{"id":"lansoprazole-and-naproxen-and-aspirin","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dyspepsia"}]},"_chembl":{"chemblId":"CHEMBL25","moleculeType":"Small molecule","molecularWeight":"180.16"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lansoprazole is a proton pump inhibitor that suppresses gastric acid production by blocking H+/K+-ATPase in parietal cells. Naproxen and aspirin are nonsteroidal anti-inflammatory drugs that inhibit cyclooxygenase (COX) enzymes to reduce inflammation and pain. The combination is designed to provide NSAID efficacy while the lansoprazole component mitigates the gastrointestinal toxicity associated with chronic NSAID use.","oneSentence":"This combination product reduces gastric acid secretion via lansoprazole while providing anti-inflammatory and analgesic effects through naproxen and aspirin, with the proton pump inhibitor protecting against NSAID-induced gastrointestinal injury.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:14.840Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reduction of NSAID-induced gastric ulcers in patients requiring chronic NSAID therapy for pain and inflammation"}]},"trialDetails":[{"nctId":"NCT00175032","phase":"PHASE3","title":"A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low Dose Aspirin","status":"COMPLETED","sponsor":"Takeda","startDate":"2003-07","conditions":"Osteoarthritis, Peptic Ulcer","enrollment":1045}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Lansoprazole and naproxen and aspirin","genericName":"Lansoprazole and naproxen and aspirin","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination product reduces gastric acid secretion via lansoprazole while providing anti-inflammatory and analgesic effects through naproxen and aspirin, with the proton pump inhibitor protecting against NSAID-induced gastrointestinal injury. Used for Reduction of NSAID-induced gastric ulcers in patients requiring chronic NSAID therapy for pain and inflammation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}